Aurinia Pharmaceuticals

Aurinia Pharmaceuticals

Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

$2.1B

Market Cap • 11/16/2026

2011

(15 years)

Founded

2009

(17 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Canada

Canada

Country

Valuation

P/B

3,2

P/S

7

P/EBITDA

13

P/OCF

12,6

P/FCF

12,6

P/E

6,8

BVPS

4,9

EPS

2,2

Market Cap

Market Cap

2,1B

EV

1,6B

EV/Revenue

5,5

EV/EBITDA

10,3

EV/EBIT

11,5

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0,7%

Total Yield

0,7%

Payout

0%

Retained Earnings

-545,9M

Profitability

Gross Margin

90,5%

EBITDA Margin

53,7%

EBIT Margin

48%

Net Margin

102,1%

D&A/EBITDA

0%

R&D/Revenue

14,9%

Capex/Revenue

0%

Capex/D&A

0,6%

Capex/OCF

0,1%

SBC/OCF

8,7%

% PPE

7,7%

% Goodwill

0%

ROE

59,3%

ROIC

75,5%

Growth

CAGR Revenue 5Y

32,7%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

6,1

Quick Ratio

5,6

Interest Coverage

3969,7%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium